The latest from CDMOs, CMOs, and suppliers featuring Fujifilm, Genezen, and Hilleman Laboratories.

Biologics Manufacturing

Fujifilm Begins Ops at New Cell-Culture Media Mfg Facility
Fujifilm Irvine Scientific, part of Fujifilm Corporation, has begun operations at its new cell-culture media manufacturing facility in Tilburg, the Netherlands.

The facility joins sites in the US and Japan and serves as a hub for both European and global markets.

The cell culture media facility manufactures dry-powder media, liquid media, buffers, and water for injection. The facility increases the company’s production capacity with approximately 320,000 kg/year of dry-powder media and approximately 470,000 L/year of liquids.

Source: Fujifilm Corporation

---

Genezen Opens New Process Development, Analytical Lab
Genezen a cell- and gene-therapy CDMO, has opened a new process development and analytical lab.

The lab supports cGMP and commercial readiness, upstream and downstream process improvements, research-grade and preclinical vector production, and analytical assay development and validation.

The lab is the first phase of a multiphase master plan for a 75,000+ square foot lentiviral and retroviral vector production facility. The next phase, with cGMP production suites, is currently underway and due to be completed in early 2022.

Once finished, the facility will deliver aseptic manufacturing of lentiviral and retroviral vectors from multiple production suites and will offer capabilities for host-cell expansion, host-cell banking, and viral vector production via transient transfection and producer cell lines. Analytical testing services, including recombinant competent lentivirus testing, vector stability testing, and safety and sterility testing, will also be available from the site.

Source: Genezen

---

Hilleman Investing in Biomanufacturing Pilot Plant
Hilleman Laboratories, a medical research organization, is investing close to SGD 80 million ($58 million) in a biomanufacturing pilot manufacturing facility for vaccine development in Singapore.

Established with the support of the Singapore Economic Development Board, the hub comprises a 30,000-square-foot current facility and a R&D facility that began operations in April 2021. Hilleman Laboratories is investing in operations, infrastructure, and capacity building over the next five years (as reported on December 6, 2021).

The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023. The R&D facility focuses on early-product development of vaccines and biologics, including candidate selection, design, early manufacturing process development, and preclinical studies.

Source: Hilleman Laboratories